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Background. Oseltamivir, a widely used anti-influenza drug, is hydrolytically activated by carboxylesterase 1
(CES1). The expression of this carboxylesterase is developmentally regulated. This study was performed to
determine when after birth infants acquire competence of activating this prodrug.
Methods. Liver tissue samples were collected and divided into 5 age groups: group 1 (1–31 d old), group 2 (35–
70 d old), group 3 (89–119 d old), group 4 (123–198 d old), and group 5 (.18 years of age). These samples were
analyzed for oseltamivir hydrolysis and CES1 expression.
Results. Liver samples in group 1 expressed the lowest level of CES1 with the lowest hydrolytic activity toward
oseltamivir. A 4–7-fold increase between groups 1 and 2 (1–31 vs 35–70 d of age) was detected in the hydrolysis and
expression analyses, respectively. Liver samples in the other 3 pediatric groups (35–198 d of age) exhibited similar
expression and hydrolysis levels. Overall, liver samples in group 1 had CES1 expression and hydrolysis levels that
were 10% of those of adults, whereas liver samples in the other 3 pediatric groups had levels that were50% of adult
levels.
Conclusions. The post-neonatal surge in CES1 expression ensures the hydrolytic capacity to be gained rapidly
after birth in infants, but the larger variability during this period suggests that caution should be exercised on the
extrapolated dosing regimens of ester drugs from other age groups.
Carboxylesterases constitute a large class of hydrolytic
enzymes [1, 2]. These enzymes are major pharmacoki-
netic determinants of ester/amide dugs and detoxify
against many insecticides [1–3]. In addition, these en-
zymes hydrolyze endogenous lipids and are involved in
the assembling of lipoproteins [4, 5]. Carboxylesterases
exhibit overlapping substrate specificity; however, many
drugs are hydrolyzed predominately by a single
carboxylesterase [1, 2, 6]. Although there are exceptions,
the relative sizes between the alcohol and acyl (acid)
moieties of an ester contribute significantly to the iso-
form-specific hydrolysis. For example, the anticancer
prodrug irinotecan has a larger alcohol moiety and is
hydrolyzed primarily by carboxylesterase 2 (CES2) [7].
In contrast, the anti-influenza prodrug oseltamivir has
a larger acid group and is hydrolyzed by carboxylesterase
1 (CES1) [8].
The recent influenza pandemic led to the wide use of
oseltamivir among patients of all age groups [9, 10].
Initial reports showed that infants and children, even
those only months old, produced sufficient levels of the
hydrolytic metabolite [11, 12]. A previous study from
this laboratory has shown that fetal livers had only5%
of the adult CES1 capacity, depending on the experi-
mental parameters (messenger RNA [mRNA], protein,
or hydrolysis levels) [13]. The present study was
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performed to test the hypothesis that a surge in expression of
CES1 during the early developmental period enables a rapid gain
of oseltamivir activation capacity. To test this hypothesis, liver
tissues from donors at birth to age 6 months were collected
and analyzed for the activation of oseltamivir and the expression
of CES1.
MATERIALS AND METHODS
Liver RNA and S9 Fractions
A total of 59 tissue sampleswere used in this study (Table 1). Liver
tissues were acquired primarily from the University of Maryland
Brain and Tissue Bank for Developmental Disorders (Baltimore,
MD). The isolation of total RNA from the liver tissues is de-
scribed elsewhere [14], and the quality was determined by
electrophoresis. S9 fractions were prepared by differential cen-
trifugation, as described elsewhere [14]. The use of the human
tissue samples was approved by the Institutional review board.
Reverse-transcription Quantitative Polymerase Chain Reaction
and Western Blot Analysis
The mRNA levels were determined by reverse-transcription
quantitative polymerase chain reaction (RT-qPCR) with a Taq-
Man gene expression assay (Applied Biosystems) [11]. The
TaqMan assay identification numbers were as follows: CES1,
Hs00275607_m1 (NM_001266); and polymerase (RNA) II,
Hs01108291_m1 (NM_000937). The CES1 probe could detect
both carboxylesterase 1A1 (CES1A1) and CES1A2 transcripts
[15]. The CES1A1- and CES1A2-specific TaqMan probes were
custom-prepared by Applied Biosystems according to reported
sequences [15]. All samples were analyzed in triplicate, and the
signals were normalized to those of polymerase (RNA) II [20]
and then expressed as relative levels of mRNA. For Western blot
analysis, S9 fractions (.25 lg) were resolved by 7.5% sodium
dodecyl sulfate polyacrylamide gel electrophoresis - in a mini gel
apparatus and transferred electrophoretically to nitrocellulose
membranes. After nonspecific binding sites were blocked with
5% nonfat milk, the blots were incubated with an antibody
against CES1 and glyceraldehyde-3-phosphate dehydrogenase,
respectively. The preparation of the antibody against CES1 is
described elsewhere [16]. The primary antibodies were sub-
sequently localized with goat anti-rabbit immunoglobulin G
conjugated with horseradish peroxidase, and horseradish
peroxidase activity was detected with a chemiluminescent kit
(SuperSignal West Pico, ThermoFisher Scientific). The chemi-
luminescent signals were captured by a Kodak Image Station
2000, and the relative intensities were quantified by means of
Kodak 1D Image Analysis Software 3.6.5. K2.
Enzymatic Assays and Monitoring of Hydrolysis by Liquid
Chromatography Mass Spectrometry
The enzyme incubations were conducted as described elsewhere,
with minor modifications [8]. All enzymatic assays were per-
formed at 37C in a total volume of 100 lL. Pilot studies were
performed to determine conditions (eg, protein concentrations)
to maintain the metabolism in the linear range. Generally, S9
fractions (5 lg of protein) were prepared in 50 lL of incubation
buffer (Tris-HCl; concentration, 50 mmol/L; pH, 7.4) and then
mixed with an equal volume of oseltamivir solution at a con-
centration of 2 lmol/L (in the same buffer). The incubations
usually lasted for 15min, and the reactions were terminated with
150 lL of acetonitrile containing the internal standard deuter-
ated oseltamivir carboxylate. The reaction mixtures were sub-
jected to centrifugation for 15min at 4C (15,000 g). Oseltamivir
and oseltamivir carboxylate were obtained from Toronto
Research Chemicals. The deuterated oseltamivir carboxylate was
provided by Hoffmann–La Roche. Various controls were per-
formed such as 0 min of incubation and incubation without
microsomes. The hydrolysis of oseltamivir was monitored by
a liquid chromatography mass spectrometry system (API 3200),
essentially as described elsewhere [15]. The analytes were de-
tected in positive ion mode using the following mass transitions:
m/z for oseltamivir, 313/ 166;m/z for oseltamivir carboxylate,
285/138; andm/z for internal standard (IS), 288/ 139. Flow
injection analysis was performed at a flow rate of 20 lL/min to
obtain optimum source parameters. The calibration curve was
1–250 ng/mL with good linearity for oseltamivir and 4–1000 ng/
mL for oseltamivir carboxylate.
Statistical Analysis
Statistical analyses were performed with PASW Statistics software
(version 18; SPSS). Significant differences were tested according to
the Spearman test for correlation or 1-way analysis of variance
followed by a Duncan test for comparison of means. In all cases,
significant differences were observed when P values were ,.05.
RESULTS
Surge in the Level of CES1 mRNA During the Post-neonatal
Period
To ascertain the activation capacity of the anti-influenza agent
oseltamivir during the early developmental period, we collected
a large number of individual liver tissue samples from donors of
age 1–198 d. The samples were divided into several groups:
group 1 (1–31 d old), group 2 (35–70 d old), group 3 (89–119
d old), group 4 (123–198 d old) and group 5 (.18 years old).
Table 1. Demographic Distribution of Liver Donors
Group
(age)
No. of
donors
No. male/no.
female
No.
white
No. African
American
No.
Hispanic
1 (1–31 d) 12 6/6 6 4 2
2 (35–70 d) 13 5/8 5 8 0
3 (89–119 d) 10 7/3 4 6 0
4 (123–198 d) 10 8/2 4 5 1
5 (.18 years) 14 7/7 10 4 0
938 d JID 2011:203 (1 April) d Shi et al.
We have shown elsewhere that oseltamivir is hydrolytically ac-
tivated by CES1 [10]. The expression of CES1 in these samples
was first determined by RT-qPCR. The results are summarized
in Figure 1A and Table 2. Samples in group 1 (1–31 d old)
expressed the lowest level, whereas those in group 5, the adult
group, expressed the highest level of CES1 mRNA. Samples in
group 1 expressed only 7% of the adult level (Table 2). Sam-
ples in groups 2–4, the other 3 pediatric groups, expressed much
higher levels of CES1 mRNA, 43%– - 55% of the adult CES1
mRNA level (Table 2). More importantly, a 7-fold increase in
CES1 mRNA level was detected between groups 1 and 2, sup-
porting our hypothesis that there is a surge in CES1 expression
during the early developmental period. There were large in-
terindividual variations in the level of CES1 mRNA, ranging
from 4-fold to 24-fold, particularly in groups 1 and 2 (Table 2).
The larger individual variation in groups 1 and 2 suggests that
developmental regulation plays a greater role in the expression
of CES1 during the period from 1 to 70 d of age. To test this
possibility, we performed correlation analyses with the entire set
of data points (groups 1–4) or the data points of groups 1 and 2.
As shown in Figure 1B, when pediatric groups were considered
together, the levels of CES1mRNAwere correlated with age with
a coefficient of correlation of .499. However, groups 1 and 2
exhibited much better correlation, with a coefficient of corre-
lation as high as .581 (Figure 1B). The adult group (group 5)
consisted of donors 18–39 years of age and exhibited no age-
related increase in CES1 mRNA level.
Differential Effect of Age on the Expression of CES1A1 and
CES1A2
The CES1 activity is contributed by 2 isoforms: CES1A1 and
CES1A2. Although CES1A1 and CES1A2 are distinct genes, they
produce the same mature carboxylesterase [15]. To specify the
relative expression of CES1A1 and CES1A2, isoform-specific
TaqMan probes were used to detect the respective transcripts.
The CES1A1 transcript was detected in all samples, but the
CES1A2 transcript was detected only in 25% of the samples in
group 1 and40% of the samples in other groups. The pediatric
samples expressed CES1A1 mRNA at one-half of the adult level,
and surprisingly, samples in the pediatric groups expressed
higher levels of CES1A2 mRNA than those in the adult group
(Figure 1C). CES1A1 and CES1A2 mRNA levels correlated rel-
atively well in the majority of the samples (Figure 1D, inside the
circle); however, one-third of the samples showed predominant
expression of either CES1A1 or CES1A2 (Figure 1D, outside the
circle).
Correlation Between CES1 mRNA and Protein
We next performed Western blot analyses and examined whether
the levels of CES1 mRNA (CES1A1 and CES1A2 combined)
are translated into the levels of protein. As shown in Figure 2A, the
patterns of the levels of CES1 protein among various age groups
were similar to the patterns of the levels of CES1 mRNA
(Figures 1A and 2A). However, there was a difference in the sta-
tistical significance. The mRNA levels among groups 2, 3, and 4,
although increased with age, showed no statistical significance
(Figure 1A). In contrast, the difference in the protein levels of
CES1 reached statistical significance between groups 2 and 4
(Figure 2A). Such a discrepancy was likely due to the intrinsic
difference between these 2 approaches. RT-qPCR generally has
better quantitative power than Western blot analysis. Overall, the
protein levels correlated well with the levels of mRNA, and the
correlation was statistically significant (Figure 2B).
Hydrolysis of Oseltamivir as a Function of Age
Next we examined whether the levels of CES1 protein among
various age groups represent the relative activity toward osel-
tamivir. Consistent with the lowest level of CES1 protein and
mRNA in group 1, samples in this group showed the lowest
hydrolysis of oseltamivir (Table 2 and Figure 2C). The hydro-
lysis by this group was 12% of that by the adult group and25%
Figure 1. Levels of carboxylesterase 1 (CES1) messenger RNA (mRNA;
isoforms (CES1A1 and CES1A2) in various age groups and correlation
analysis. A, The mRNA expression level of CES1. Total RNA was
subjected to reverse-transcription quantitative polymerase chain reaction
(RT-qPCR) analysis for the level of CES1 mRNA by a TaqMan probe
recognizing both CES1A1 and CES1A2. The signals from each target were
normalized based on the signal from polymerase II and expressed as
relative levels among all samples. The data are presented as mean (6
SD). *P, .05. B, Correlation analysis between age and the level of CES1
mRNA. C, The mRNA levels of CES1A1 and CES1A2. Total RNA was
subjected to RT-qPCR with a CES1A1 and CES1A2 isoform-specific
TaqMan probe. The signals from each target were normalized based on
the signal from Pol II and expressed as relative levels among all samples.
The data are presented as mean (6 SD). *P, .05. D,Correlation analysis
between CES1A1 and CES1A2 in samples that expressed both transcripts.
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of that by other pediatric groups (Table 2 and Figure 2C).
Samples in the other 3 pediatric groups showed comparable
hydrolysis of oseltamivir and had one-half of the hydrolytic
activity of samples in the adult group (Table 2 and Figure 2C).
Among all groups, the largest interindividual variation (1689-
fold) was detected in group 2. The second largest interindividual
variation was 62-fold, which was detected in group 1 (Table 2).
Such a large variation in group 2 was attributed to a single
sample with extremely low activity toward oseltamivir, and
variability was decreased to 25-fold when this data point was not
considered. RT-qPCR and Western blot analysis detected evi-
dent expression of CES1 in this sample. Importantly, this sample
effectively hydrolyzed p-nitrophenylacetate, a standard substrate
for carboxylesterases [17].
We next performed the correlation analysis between CES1
protein and oseltamivir hydrolysis. As expected, the protein level
was correlated well with the hydrolytic activity with a coefficient
of correlation of .854 (Figure 2D). Indeed, all data points were
closely scattered along the correlation line with only 2 exceptions
(Figure 2D, arrows). In addition, we tested whether the overall
hydrolysis of oseltamivir differs between male and female do-
nors. Interestingly, samples from female donors appeared to
show a higher hydrolytic activity in both pediatric and adult
groups (Figure 2E). The female-related higher hydrolysis in the
adult group was more profound than that in the pediatric
groups. However, apparent sex differences were not statistically
significant in any age groups.
DISCUSSION
We and other investigators have recently reported that the ex-
pression of human carboxylesterases is developmentally regu-
lated [13, 18]. In this study, we analyzed a large number of
individual liver samples from pediatric donors (at birth to 198
d of age) and demonstrated a surge in the expression of CES1
during the post-neonatal stage. Samples from donors at 1–31
d of age had the lowest capacity of CES1 on both expression and
oseltamivir hydrolysis. In contrast, samples from donors at
35–70 d of age (next age group) showed a 4–7-fold increase in
CES1 capacity (Table 2). Three other pediatric groups (groups 2,
3, and 4), consisting of samples from donors of age 35-198 d,
exhibited slight increases with age in the expression and hy-
drolysis. However, the increases were minimal (3%) and
statistically insignificant (Figures 1A and 2C).
The age-related increases without statistical significance in
groups 2, 3, and 4 suggest that the developmental regulation of
CES1 occurs in 2 phases. The post-neonatal phase occurs quickly
and dramatically (large magnitude in a short period). Such
a surged expression ensures the hydrolytic capacity of CES1 to
be gained rapidly after birth. The second phase, probably
starting at the end of the surged expression, is slow and in-
cremental. In support of this notion, we have previously re-
ported that pediatric donors, largely consisting of those up to 10
years of age, expressed 70% of the adult level of CES1 mRNA
[15]. Likewise, Zhu et al [18] reported that the level of CES1
protein in donors aged 12–18 years remained slightly lower than
that in adult donors. In this study, we have shown that donors at
>2 months of age had approximately one-half of the adult CES1
capacity. This finding, along with those of previous studies,
suggests that the second phase lasts for almost the entire de-
velopment period (up to 18 years of age) but only accounts for
a 50% gain of total CES1 capacity compared with adults.
The precise mechanisms on the post-neonatal surge remain to
be determined. There are many changes immediately after birth
and in the early days and weeks of life, notably in hormones and
food intake. Interestingly, many genes are expressed with a neo-
natal or post-neonatal surge as is CES1. For example, fibroblast
growth factor 21 (FGF21) is induced rapidly and drastically after
birth [19]. It was recently reported that the induction was ini-
tiated by suckling and required lipid intake. Importantly, the
neonatal induction of FGF21 was diminished in mice lacking
functional peroxisome proliferator-activated receptor alpha
[19]. It happens that this receptor is also implicated in the reg-
ulation of the expression of carboxylesterases in rodents [20–22].
Another interesting observation was that the composition of
dietary lipids appeared to alter the surged expression of FGF21
Table 2. Carboxylesterase 1 Messenger RNA Levels and Oseltamivir Hydrolysis
Messenger RNA level/arbitrary units Oseltamivir hydrolysis
Group (age) Mean Variability, fold increasea Mean, pmol products formed/mg protein/min Variability, fold increasea
1 (1–31 d) 1.54 14 5.98 62
2 (35–70 d) 10.87 24 23.38 1689b
3 (89–119 d) 11.29 4 23.00 4
4 (123–198 d) 12.74 4 24.87 15
5 (.18 years) 23.04 12 47.00 5
NOTE. a Variability was calculated as the maximum value divided by the minimum value in each group.
b The fold increase of the variability was 25 after a single sample with extremely low activity was not considered.
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[19], pointing to a potential difference between formula milk
and breastfeeding.
CES1 has been shown to play critical roles in the metabolism
of lipids in CES1 transgenic animals [5]. Therefore, it is con-
ceivable that the post-neonatal surge of CES1 is a functional
adaptation to deal with lipid intake. However, CES2 also shows
a potential post-neonatal surge in expression [13], but CES2
primarily hydrolyzes drugs and other xenobiotics [1, 2]. In ad-
dition to nutrient stimuli, hormonal factors are likely involved in
the post-neonatal surge of CES1 and other carboxylesterases
[23]. However, some hormones may act independently of age. In
this study, we have shown that samples from female donors had
higher expression of CES1 and higher hydrolysis of oseltamivir
in both pediatric and adult groups, although samples in the adult
group showed much greater sex difference than samples in the
pediatric group (26% vs 14%, respectively) (Figure 2E).
Like those of many other drug-metabolizing enzymes, the ex-
pression and the hydrolytic activity of CES1 exhibited large in-
terindividual variation. Based on the high degree of correlation
between the protein level and hydrolysis (r 5 .854) (Figure 2D),
the observed variation in the hydrolysis of oseltamivir likely
resulted from differences in the expression. On the other hand,
the scattering patterns of the correlation in Figure 2D point to the
existence of outliers with potentially large alteration in the catalytic
activity toward oseltamivir. It is likely that these represent poly-
morphic variants of CES1. It should be noted that a single sample
in group 2 showed extremely low activity toward oseltamivir,
although this individual had evident expression of CES1 (Table 2).
Zhu andMarkowitz [24] recently reported that 2 CES1mutations,
namely, Gly143Glu and p.Asp260fs, showed impairment in the
hydrolysis of oseltamivir. We also reported several CES1 variants
with altered hydrolysis of oseltamivir [8]. For example, the variant
with an Ser58Asn substitution, compared with the wild-type
CES1, had a higher specific rate toward oseltamivir [8]. These
findings collectively suggest that certain CES1 variants may differ
from the wild-type CES1 in the hydrolysis of oseltamivir, leading
to altered hydrolytic activation of this prodrug.
All the pediatric samples except those in group 1 had ap-
proximately one-half of the hydrolytic activity of the adult
samples, suggesting that these infants can efficiently activate this
prodrug. In support of this notion, a retrospective analysis has
shown that the outcome of oseltamivir treatment was similar
between infants (,1 year old) and older children [12]. As for
individuals from birth to 31 d of age (group 1), the clinical
effectiveness in the hydrolytic activation remains to be estab-
lished. Based on the reported time to reach the maximum
plasma concentration values of oseltamivir and its hydrolytic
metabolite, it is clear that the activation of oseltamivir is ach-
ieved primarily during the first pass in the liver [25]. Such a high
efficient conversion is due to the high hepatic concentration of
oseltamivir right after oral administration. In neonates, the level
of CES1 likely becomes a limiting factor. On the other hand, the
plasma concentrations of the active metabolite also depend on
the rate of elimination, particularly the renal clearance [26].
In summary, our work points to several important conclusions.
First, the expression of CES1 surges during the post-neonatal
period and such a surge ensures the hydrolytic capacity of this
enzyme to be gained rapidly in infants. Second, there exists a large
Figure 2. Levels of carboxylesterase 1 (CES1) protein and hydrolysis of
oseltamivir. A, Western blot analysis S9 fractions (.25 lg) resolved by
7.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis - and
transferred electrophoretically to nitrocellulose membranes. The blots
were incubated with an antibody against CES1 or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and developed with chemilumines-
cent substrate. The signal was captured by a Kodak Image Station 2000,
and the relative intensities were quantified by Kodak 1D Image Analysis
software. *P , .05. B, Correlation analysis of CES1 protein and
messenger RNA (mRNA). C, Hydrolysis of oseltamivir S9 fraction (5 lg)
from various age groups incubated with oseltamivir (1 lmol/L) at 37C for
15 min; the formation of oseltamivir carboxylate was detected by liquid
chromatography mass spectrometry. *P , .05. D, Correlation between
CES1 protein and hydrolysis of oseltamivir. E, Difference in relative
activity toward oseltamivir between samples from male (n 5 33) and
female (n 5 26) donors.
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interindividual variability in the expression and hydrolysis of
CES1 and the variability is greater in groups 1 and 2 (1–70 d of
age). Such large variability during this period suggests that caution
should be exercised in the extrapolation of the dose of ester drugs
from other age groups. Third, the surge in expression, although it
is significant, confers only one-half of the hydrolytic activity of the
adult level, pointing to major differences between infants and
adults in the overall hydrolytic biotransformation by CES1.
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